Completed NA INTERVENTIONAL 2-arm NCT00140504

Preventing Adverse Drug Events With PatientSite

Sponsor: Agency for Healthcare Research and Quality (AHRQ)

Updated 5 times since 2017 Last updated: Feb 24, 2013 Started: Apr 30, 2003 Primary completion: Dec 31, 2004 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00140504, this NA trial focuses on Adverse Drug Event and remains completed. Sponsored by Agency for Healthcare Research and Quality (AHRQ), it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Agency for Healthcare Research and Quality (AHRQ)
Beth Israel Deaconess Medical Center
Blue Cross Blue Shield
Dana-Farber Cancer Institute

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States